Investors

Press Releases

 
Press Releases
  Date Title View
Nov 11, 2010
Watertown, MA – November 11, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) Gram-negative pathogens, today announced th...
Oct 12, 2010
Watertown, MA – October 12, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) ...
Oct 1, 2010
Watertown, MA – October 1, 2010 –Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) Gram-negative pathogens, today announced that ...
Sep 16, 2010
Watertown, MA – September 16, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative p...
Sep 15, 2010
Watertown, MA – September 15, 2010 – Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens. The data supported the utility ...
Sep 15, 2010
Watertown, MA –  September 15, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative ...
Sep 13, 2010
Watertown, MA – September 13, 2010 –Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once-daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant Gram-negative pathogens while als...
Sep 8, 2010
Watertown, MA – September 8, 2010 – Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agent...
Jun 1, 2010
Watertown, MA – June 1, 2010 – Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing. Excel Venture...
Apr 29, 2010
Watertown, MA – April 29, 2010 – Tetraphase Pharmaceuticals Inc., a biopharmaceutical company developing novel antibiotics based on proprietary synthetic chemistry technology, today announced that it will be participating in a session on drug discovery and development of novel treatments for drug-resist...
FirstPrevious
...
14
NextLast
= add release to Briefcase